Nyrada Inc.
NYR.ASXHealth Care
Drug research and development
Market Data
$0.495
-0.0%$122.7M
-100000.0x
$-0.025
0.00%
-0.4%
Latest Earnings
Appendix 4D and Half Year Report to 31 December 2025
18 February 2026
Nyrada Inc., a clinical-stage biotechnology company, reported a 30% increase in half-year loss to $3.19M despite slightly lower revenue of $846K. The company successfully raised significant capital during the period, ending with $7.1M in cash, and completed a Phase I clinical trial for its lead drug Xolatryp with positive safety results, positioning it for Phase IIa trials in heart attack patients starting March 2026. Key points: Successfully completed Phase I clinical trial of Xolatryp with strong safety profile and no serious adverse events; Raised significant capital with cash position improving from $2.9M to $7.1M; Human Research Ethics Committee approval received for Phase IIa trial in heart attack patients
Recent Announcements
Appendix 4D and Half Year Report to 31 December 2025
Nyrada Inc., a clinical-stage biotechnology company, reported a 30% increase in half-year loss to $3.19M despite slightly lower revenue of $846K. The company successfully raised significant capital during the period, ending with $7.1M in cash, and completed a Phase I clinical trial for its lead drug Xolatryp with positive safety results, positioning it for Phase IIa trials in heart attack patients starting March 2026. Key points: Successfully completed Phase I clinical trial of Xolatryp with strong safety profile and no serious adverse events; Raised significant capital with cash position improving from $2.9M to $7.1M; Human Research Ethics Committee approval received for Phase IIa trial in heart attack patients
Get real-time alerts for NYR
Receive AI-powered earnings summaries and instant notifications when Nyrada Inc. releases results.
Register Free